FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rosalyn Juergens

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Physiology

Disease Progression

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Charles M Rudin; Rosa Sebree; Ruth Smith; Blake Aftab; Julie R Brahmer; David S Ettinger; Christine L Hann; Peng Huang; Rosalyn A Juergens; Jun O Liu
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.
Mark N Levine; Rosalyn A Juergens
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Rosalyn A Juergens; Beverly Lee; Sara C Murphy; Kristen Rodgers; Michelle A Rudek; Rosa Sebree; Salina D Tsai; Frank P Vendetti; John Wrangle; Ming Zhao; Stephen B Baylin; Steven A Belinsky; Malcolm V Brock; Barbara Coleman; Igor Espinoza Delgado; Noreli Franco; James G Herman; Craig M Hooker; Charles Rudin
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rosalyn Juergens (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Charles M Rudin; Rosa Sebree; Ruth Smith; Blake Aftab; Julie R Brahmer; David S Ettinger; Christine L Hann; Peng Huang; Rosalyn A Juergens; Jun O Liu
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(5):619-23.
2012: Mark N Levine; Rosalyn A Juergens
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(17):2025-7.
2011: Rosalyn A Juergens; Beverly Lee; Sara C Murphy; Kristen Rodgers; Michelle A Rudek; Rosa Sebree; Salina D Tsai; Frank P Vendetti; John Wrangle; Ming Zhao; Stephen B Baylin; Steven A Belinsky; Malcolm V Brock; Barbara Coleman; Igor Espinoza Delgado; Noreli Franco; James G Herman; Craig M Hooker; Charles Rudin
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Cancer discovery 2011;1(7):598-607.
2011: Paul K Paik; Maria C Pietanza; Naiyer A Rizvi; Charles Rudin; Sara Subzwari; Naoko Takebe; William Travis; Leslie Tyson; Andrew Brown; Michelle S Ginsberg; Leonard James; Rosalyn A Juergens; Mark G Kris; Susan Markus; Lee M Krug
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2011;74(3):481-5.
2011: Charles Rudin; Ann Mauer; Martin Smakal; Rosalyn A Juergens; Stanislav Spelda; Michael Wertheim; Andrew Coates; Evelyn McKeegan; Peter Ansell; Xiangdong Zhou; Jane Qian; Rajendra Pradhan; Barry Dowell; Andrew Krivoshik; Gary Gordon
Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(8):1075-82.
2010: Timothy F Burns; Rosalyn A Juergens
Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.
Oncology (Williston Park, N.Y.) 2010;24(13):1223-4, 1226.
2010: Paul K Paik; Charles Rudin; Andrew Brown; Naiyer A Rizvi; Naoko Takebe; William D Travis; Leonard James; Michelle S Ginsberg; Rosalyn A Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G Kris; Lee M Krug
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Cancer chemotherapy and pharmacology 2010;66(6):1079-85.
2008: Rosalyn A Juergens; Arlene A Forastiere
Combined modality therapy of esophageal cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(9):851-60; quiz 861.
2007: Rosalyn A Juergens; Julie R Brahmer
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Current oncology reports 2007;9(4):255-64.
2007: Rosalyn A Juergens; Julie R Brahmer; David S Ettinger
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.
Cancer chemotherapy and pharmacology 2007;59(5):621-9.
2006: Rosalyn A Juergens; Julie R Brahmer
Adjuvant treatment in non-small cell lung cancer: Where are we now?
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(6):595-600.
2005: Rosalyn A Juergens; Julie R Brahmer
Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future.
Current oncology reports 2005;7(4):248-54.